Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy Amid Arrowhead Hepatitis B Program Discontinuations

November 30, 2016 6:23 AM EST Send to a Friend
Chardan Capital Markets upgraded Arbutus Biopharma (NASDAQ: ABUS) from Neutral to Buy with a price target of $4.00 (from $3.00) ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login